MARKET

OGEN

OGEN

ORAGENICS
AMEX

Real-time Quotes | Nasdaq Last Sale

0.6600
+0.0244
+3.84%
Closed 18:57 05/11 EDT
OPEN
0.6000
PREV CLOSE
0.6356
HIGH
0.6751
LOW
0.6000
VOLUME
1.89M
TURNOVER
--
52 WEEK HIGH
2.090
52 WEEK LOW
0.3770
MARKET CAP
76.32M
P/E (TTM)
-1.5453
1D
5D
1M
3M
1Y
5Y
10-Q: ORAGENICS INC
(EDGAR Online via COMTEX) -- ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following information should...
Edgar Online - (EDG = 10Q, 10K) · 05/03 20:14
BRIEF-Oragenics Announce Changes In Management And Board Of Directors
reuters.com · 05/03 12:19
Oragenics Says Board Will Provide Direction to Co in Interim
Oragenics Says Board Will Provide Direction to Co in Interim
Dow Jones · 05/03 11:31
Oragenics Says Sullivan to Serve as Interim Principal Executive Officer >OGEN
Oragenics Says Sullivan to Serve as Interim Principal Executive Officer >OGEN
Dow Jones · 05/03 11:31
Oragenics: Frederick Telling Transitioning From Chmn to Newly Established Position of Executive Chmn >OGEN
Oragenics: Frederick Telling Transitioning From Chmn to Newly Established Position of Executive Chmn >OGEN
Dow Jones · 05/03 11:31
Oragenics Announce Changes in Management and Board of Directors
BusinessWire - BZX · 05/03 11:30
Oragenics Says Alan Joslyn Resigned as Chief Executive Officer, Pres and Director >OGEN
Oragenics Says Alan Joslyn Resigned as Chief Executive Officer, Pres and Director >OGEN
Dow Jones · 05/03 11:30
OGEN: COVID-19 Vaccine Candidate Exhibits Protective Immunity in Mice…
By David Bautz, PhD NYSE:OGEN READ THE FULL OGEN RESEARCH REPORT
Benzinga · 04/14 14:31
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OGEN. Analyze the recent business situations of ORAGENICS through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OGEN stock price target is 2.375 with a high estimate of 2.750 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 18
Institutional Holdings: 6.33M
% Owned: 5.47%
Shares Outstanding: 115.64M
TypeInstitutionsShares
Increased
4
857.31K
New
5
128.78K
Decreased
2
2.71M
Sold Out
2
2.98M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.34%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Chairman/Executive Director
Frederick Telling
Chief Executive Officer/Chief Financial Officer/Treasurer/Secretary
Michael Sullivan
Director
Kim Murphy
Independent Director
Alan Dunton
Independent Director
Robert Koski
Independent Director
Charles Pope
No Data
About OGEN
Oragenics, Inc. is a healthcare company. The Company is focused on developing treatments for oral mucositis and novel antibiotics against infectious disease. The Company is focused on developing of the TerraCoV2 immunization product candidate. The Company’s product candidate includes, OG716, as an antibiotic, as well as other homolog antibiotic product candidates and AG013 for the treatment of oral mucositis in patients undergoing treatment for cancer. The Company have developed other product such as weight loss candidate, LPT3-04 and SMaRT Replacement Therapy.

Webull offers kinds of Oragenics Inc stock information, including AMEX:OGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OGEN stock methods without spending real money on the virtual paper trading platform.